Applying mHealth to Tobacco-related Health Disparities
- Conditions
- Smoking Cessation
- Interventions
- First Posted Date
- 2018-01-19
- Last Posted Date
- 2023-05-11
- Target Recruit Count
- 50
- Registration Number
- NCT03404596
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
- Conditions
- Breast Cancer FemaleHER2-positive Breast CancerBreast Cancer, MaleHER2 Positive Breast CarcinomaBreast CancerInvasive Breast CancerStage II Breast CancerStage III Breast Cancer
- Interventions
- Biological: Dendritic Cell Vaccine (DC1)Drug: Neoadjuvant ChemotherapyProcedure: Curative Surgery
- First Posted Date
- 2018-01-02
- Last Posted Date
- 2025-04-03
- Target Recruit Count
- 31
- Registration Number
- NCT03387553
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
- Conditions
- Breast Cancer Stage IIHER2-positive Breast CancerBreast Cancer Stage IIIHER2 Positive Breast CarcinomaBreast Cancer FemaleBreast Cancer, MaleResidual DiseaseBreast Cancer Stage I
- Interventions
- Biological: DC1 Vaccine
- First Posted Date
- 2017-12-28
- Last Posted Date
- 2025-05-06
- Target Recruit Count
- 119
- Registration Number
- NCT03384914
- Locations
- 🇺🇸
University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Emory - Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Ohio State University - Arthur G James Cancer Hospital & Richard J Solove Research Institute, Columbus, Ohio, United States
IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma
- Conditions
- Squamous Cell CarcinomaMetastatic Squamous Cell CarcinomaHypopharynx Squamous Cell CarcinomaSquamous Cell Carcinoma of the Head and NeckOropharynx Squamous Cell CarcinomaOral Cavity Squamous Cell CarcinomaParanasal Sinus Squamous Cell CarcinomaLarynx Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2017-12-21
- Last Posted Date
- 2025-05-20
- Target Recruit Count
- 19
- Registration Number
- NCT03381183
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
- Conditions
- Non Small Cell Lung CancerLung Cancer, Nonsmall CellNon Small Cell Lung Cancer Metastatic
- Interventions
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2025-03-25
- Target Recruit Count
- 66
- Registration Number
- NCT03377023
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
- Conditions
- Squamous Cell Carcinoma of the HypopharynxHead and Neck Squamous Cell CarcinomaSquamous Cell Carcinoma of the LarynxSquamous Cell Carcinoma of the Paranasal SinusSquamous Cell Carcinoma of the OropharynxSquamous Cell Carcinoma of the Oral CavitySquamous Cell CancerHead and Neck Carcinoma
- Interventions
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2025-03-18
- Target Recruit Count
- 95
- Registration Number
- NCT03370276
- Locations
- 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers
- Conditions
- Colorectal CarcinomaColon CancerColorectal CancerColon Disease
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2022-06-03
- Target Recruit Count
- 40
- Registration Number
- NCT03332498
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient
- Conditions
- Breast CancerBreast NeoplasmsBreast Cancer, FemaleBreast Cancer, Male
- Interventions
- Diagnostic Test: Fluoro-D-glucose-positron Emission TomographyBiological: 2-deoxy-2-[18F]fluoro-D-glucose (FDG)Diagnostic Test: Echocardiogram
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
- Conditions
- Neuroendocrine TumorsNeuroendocrine CarcinomaNeuroendocrine Cancer
- Interventions
- First Posted Date
- 2017-09-21
- Last Posted Date
- 2025-05-21
- Target Recruit Count
- 20
- Registration Number
- NCT03290079
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Biobank for African American Prostate Cancer Research in Florida
- Conditions
- Prostate Cancer
- First Posted Date
- 2017-07-28
- Last Posted Date
- 2025-05-07
- Target Recruit Count
- 592
- Registration Number
- NCT03232411
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States